Please login to the form below
Sparsentan
This page shows the latest Sparsentan news and features for those working in and with pharma, biotech and healthcare.
Retrophin rockets away as rare disease trial hits targets
Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Sparsentan was brought into Retrophin's pipeline
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Biogen and Happify Health team up to create digital platform for MS patients
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
- Moderna to launch Innovation and Technology Center in the UK
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Gilead Sciences supports Kigali Declaration for neglected tropical diseases
- As the NHS turns 74, it launches its ‘biggest NHS Big Tea ever’ to raise funds
- FDA issues innovative proposal to increase nonprescription drug access
- European Commission approves potential new treatment for Pompe disease
- Connect to the conversation around mental health: A spotlight on physician burnout
- How understanding the rare disease patient’s lived experience creates better health communications
- A creative awakening – how pharma is bringing innovation to the patient journey
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- European Commission approves potential new treatment for Pompe disease
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- FDA issues innovative proposal to increase nonprescription drug access
- Myovant Sciences and Pfizer publish phase 3 results for endometriosis therapy
PMHub
Cegedim Health Data
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...
Latest intelligence
- Virtual MSL/Sales training programs and events
- Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
- Omnichannel strategies to revolutionize the healthcare professional experience
- Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
